Shalby pulls back on franchises, bets on implants hitting ₹650 cr by 2030
The MedTech division posted its second straight quarter of positive EBITDA. Management is shelving franchise expansion to focus capital on core hospitals and its long-term implant target.
— 1 earlier story on Shalby Ltd. →What's new
- MedTech division turned EBITDA-positive for a second straight quarter, moving to a profitable scale phase.
- Management is deprioritizing franchise expansion to focus on core hospitals and implants.
- Gurgaon hospital breakeven timelines were withdrawn due to geopolitical impacts on international patient flows.
Why this matters
Shalby is narrowing its focus. The profitable implant business gets a ₹600-650 cr target by 2030, but that's a more conservative trajectory than before. The trade-off is clear: less expansion, more capital discipline, but a near-term hit from the Gurgaon unit's uncertainty.
What we're watching
- Whether core hospital occupancy and government rate revisions deliver the expected FY27 revenue tailwind.
- The Q2 FY27 milestone management flagged as key to validating the broader recovery.
- How quickly the Gurgaon unit recovers from the international patient-flow disruption.
The full read
Shalby's implant business is finally making money. The MedTech division posted its second straight quarter of positive EBITDA, hitting a scale phase the company has targeted for years. Consolidated Q4 revenue hit ₹295.5 crore, and EBITDA grew 43% to ₹37.4 crore. The strategic pivot is toward capital efficiency. Management is deprioritizing franchise expansion, focusing instead on core hospitals and a long-term implant target of ₹600-650 crore by 2030. That implant goal is a downgrade from prior hopes. The caution is partly driven by Gurgaon, where international patient flows have stalled due to geopolitics. Previous breakeven timelines for that unit are gone. The open question is whether government rate revisions and better occupancy can deliver the FY27 revenue tailwind management expects.
Questions answered
- Why did Shalby withdraw the Gurgaon breakeven timeline?
- Geopolitical disruptions have impacted international patient flows to the Gurgaon hospital. Management deemed previous breakeven targets unreliable and pulled them.
- What is the new long-term target for the implant business?
- Shalby is targeting ₹600-650 crore in revenue from medical implants by 2030. This is a downward revision from earlier expectations, reflecting a more conservative growth trajectory.
- How is Shalby changing its expansion strategy?
- The company is deprioritizing franchise expansion. It will instead focus capital on its core mainline hospitals and the medical implants business.
- What drove the 43% EBITDA growth in Q4?
- Consolidated Q4 EBITDA grew 43% to ₹37.4 crore on revenue of ₹295.5 crore. The improvement was driven by operating leverage and manufacturing efficiencies, particularly in the MedTech division.
Story so far
All notes on SHALBY →- 29 May 2026 · 7:42 PM IST Shalby pulls back on franchises, bets on implants hitting ₹650 cr by 2030
- 1d ago Shalby's Q4 call is a replay. The stock needs a new script.